About this trial
This upcoming case-control study aims to confirm the Lung Sliding Index (LSI), a new ultrasound score that measures how well the pleura moves, in various lung diseases. The study will check how well the LSI can tell apart different lung diseases (like pneumothorax, interstitial lung disease, COPD, pneumonia, and pulmonary edema), how it relates to signs of disease severity, and how consistent the results are between different operators who have received the same training. Secondary objectives include assessing patient and operator satisfaction and feasibility using validated Likert scales.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age 18 years and older.
Diagnosed with one of the specified pulmonary diseases, or a healthy control
Able to provide written informed consent
Disqualifiers
Inability to tolerate or undergo a lung ultrasound
Extensive chest wall pathology precluding assessment
Unscorable >2 zones per protocol
Withdrawal of consent
Trial population
Adult patients (\>18 years) with: * Pneumothorax * Interstitial lung disease (ILD/IPF) * COPD/emphysema * Bronchiectasis * Community-acquired pneumonia * Pulmonary edema * Pleural effusion * Healthy controls
Trial design
Case-control
Prospective
Treatments tested in this trial
Lung Ultrasound
Diagnostic testAll enrolled patient will be subjected to Lung Ultrasound examination LUS
Treatment groups
8
Treatment groupsSee each treatment group below.
Trial outcomes
Primary outcomes
Discriminative performance of LSI (total score, 0-36) between disease groups
The primary outcome is establishing a pattern of LSI among the seven studied groups
Secondary outcomes
Correlation of LSI with clinical severity indices
Correlation of LSI with clinical severity indices (PaO₂/FiO₂ ratio, FVC %, mMRC, 6MWT)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Assiut University
Lead sponsor
Aliae AR Mohamed Hussein [ahussein
Collaborator